Louise Flanagan

476 citations

31 papers · 302 indexed · h-index 11

Hematology top 10%
- Multiple Myeloma Research and Treatments 21
Oncology
- Peptidase Inhibition and Analysis 6
- Cancer Treatment and Pharmacology 2
Molecular Biology
- Protein Degradation and Inhibitors 17
- Histone Deacetylase Inhibitors Research 7
- Ubiquitin and proteasome pathways 2
Endocrinology, Diabetes and Metabolism
Pulmonary and Respiratory Medicine
Genetics
- Chronic Lymphocytic Leukemia Research 2
Pathology and Forensic Medicine
- Cancer Mechanisms and Therapy 2

Co-authors: Sarah Brown Andrew Hall Kwee Yong Jamie Cavenagh Martin Kaiser Eric Low Walter M. Gregory Yong Du
Cited by: Hematology Oncology Molecular Biology
Journals: Nature Communications (1 paper)Journal of Clinical Oncology (1 paper)SHILAP Revista de lepidopterología (1 paper)
Partner nations: United Kingdom United States Ireland

In The Last Decade

Louise Flanagan

31 papers receiving 296 citations

Peers

Countries citing papers authored by Louise Flanagan

Since Specialization

Citations

This map shows the geographic impact of Louise Flanagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise Flanagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise Flanagan more than expected).

Fields of papers citing papers by Louise Flanagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louise Flanagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise Flanagan. The network helps show where Louise Flanagan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Louise Flanagan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Louise Flanagan Line = papers co-authored together Louise Flanagan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A meta-analysis of the use of intraoperative cholangiography; time to revisit our approach to cholecystectomy? SHILAP Revista de lepidopterología ·Eoin Donnellan,Jonathan Coulter,Cherian Mathew,M Choynowski,Louise Flanagan,Magda Bucholc,Alison Johnston,Michael Sugrue	2021	23
2	A mutational hotspot that determines highly repeatable evolution can be built and broken by silent genetic changes Nature Communications ·J. Stephen Horton,Louise Flanagan,Robert W. Jackson,Nicholas K. Priest,Tiffany Taylor	2021	22
3	MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia BMJ Open ·Sarah Brown,Debbie Sherratt,Samantha Hinsley,Louise Flanagan,Sadie Roberts,Katrina Walker,Andrew Hall,Guy Pratt,Christina Messiou,Matthew Jenner,Martin Kaiser	2021	17
4	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>) Haematologica ·Kwee Yong,Samantha Hinsley,Holger W. Auner,Ceri Bygrave,Martin Kaiser,Karthik Ramasamy,Ruth M. de Tute,Debbie Sherratt,Louise Flanagan,Mamta Garg,Stephen Hawkins,Catherine Williams,Jamie Cavenagh,Neil Rabin,James Croft,Gareth J. Morgan,Faith E. Davies,Roger G. Owen,Sarah Brown	2021	8
5	CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial Trials ·Rob Coleman,Janet E. Brown,Emma Rathbone,Louise Flanagan,A.W. Reid,Jessica Kendall,Sacha J. Howell,Chris Twelves,Carlo Palmieri,Anjana Anand,Iain R. Macpherson,Sarah Brown	2020	11
6	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor Trials ·Samantha Hinsley,Katrina Walker,Debbie Sherratt,Lucy Bailey,Sadie Reed,Louise Flanagan,Sophie C. McKee,Fiona Brudenell Straw,Bryony Dawkins,David Meads,Holger W. Auner,Martin Kaiser,Mark Cook,Sarah Brown,Gordon Cook	2020	3
7	Readmission to hospital following laparoscopic cholecystectomy: a meta-analysis Anaesthesiology Intensive Therapy ·Caroline McIntyre,Alison Johnston,Deirdre Foley,Jack Lawler,Magda Bucholc,Louise Flanagan,Michael Sugrue	2020	15
8	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial Clinical Lymphoma Myeloma & Leukemia ·Sarah Brown,Charlotte Pawlyn,Avie‐Lee Tillotson,Debbie Sherratt,Louise Flanagan,Eric Low,Gareth J. Morgan,C. Rosie Williams,Martin Kaiser,Faith E. Davies,Matthew Jenner	2020	15
9	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma BMC Cancer ·Hannah Buckley,Fiona Collinson,Gemma Ainsworth,Heather Poad,Louise Flanagan,Eszter Katona,Helen Howard,Geraldine Murden,Rosamonde E. Banks,Julia Brown,Galina Velikova,Tom Waddell,Kate Fife,Paul Nathan,James Larkin,Thomas Powles,Sarah Brown,Naveen Vasudev	2019	13
10	Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial BMC Cancer ·Sarah Brown,Andrew Hall,Hannah Buckley,Louise Flanagan,David González de Castro,Kate Farnell,Laura Moss,Rebecca Gregory,Kate Newbold,Yong Du,Glenn Flux,Jonathan Wadsley	2019	27
11	Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172) Blood ·Matthew Jenner,Amy L. Sherborne,Andrew Hall,Vallari Shah,Katrina Walker,Sidra Ellis,Kim A. Sharp,Amy Price,James Croft,Graham Jackson,Louise Flanagan,Mark T. Drayson,Ruth M. de Tute,Roger G. Owen,Guy Pratt,Gordon Cook,Sarah Brown,Martin Kaiser	2019	1
12	Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial Blood ·Amy L. Sherborne,Vallari Shah,Sidra Ellis,Farzana Begum,Jack Kendall,David C. Johnson,Roger G. Owen,Mark T. Drayson,Louise Flanagan,Debbie Sherratt,Walter M. Gregory,Graham Jackson,Guy Pratt,Gordon Cook,Samantha Hinsley,Julia Brown,Matthew Jenner,Martin Kaiser	2017	2
13	SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective British Journal of Radiology ·Jonathan Wadsley,Rebecca Gregory,Glenn Flux,Kate Newbold,Yong Du,Laura Moss,Andrew Hall,Louise Flanagan,Sarah Brown	2017	25
14	Experiences of establishing an academic early phase clinical trials unit Clinical Trials ·Sarah Brown,Debbie Sherratt,Gill Booth,Julia Brown,Fiona Collinson,Walter M. Gregory,Louise Flanagan	2017	8
15	Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial The Lancet Haematology ·Rakesh Popat,Sarah Brown,Louise Flanagan,Andrew Hall,Walter M. Gregory,Bhuvan Kishore,Matthew Streetly,Heather Oakervee,Kwee Yong,Gordon Cook,Eric Low,Jamie Cavenagh	2016	35
16	The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma PubMed ·Sarah Brown,Samantha Hinsley,Mónica Ballesteros,Sue Bourne,Paul McGarry,Debbie Sherratt,Louise Flanagan,Walter M. Gregory,Jamie Cavenagh,Roger G. Owen,C. Rosie Williams,Martin Kaiser,Eric Low,Kwee Yong	2016	9
17	FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin. Journal of Clinical Oncology ·Robert H. Jones,David Alan Anthoney,Robert J. Jones,Simon J. Crabb,Syed A. Hussain,Alison Birtle,Pavlina Spiliopoulou,Tim Robinson,Margaret A. Knowles,Lyndall McLellan,Hazel Jones,Z. Boylan,Dónal Landers,Kwame N. Atuah,Debbie Sherratt,Sarah Brown,Louise Flanagan,Paul M. Loadman,Chris Twelves,John Chester	2016	2
18	Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial British Journal of Haematology ·Steve Schey,Sarah Brown,Avie‐Lee Tillotson,Kwee Yong,Cathy Williams,Faith E. Davies,Gareth J. Morgan,Jamie Cavenagh,Gordon Cook,Mark Cook,Guillermo Ortí,Curly Morris,Debbie Sherratt,Louise Flanagan,Walter M. Gregory,James Cavet	2015	16
19	Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial Blood ·Rakesh Popat,Sarah Brown,Louise Flanagan,Andrew Hall,Bhuvan Kishore,Matthew Streetly,Heather Oakervee,Simon Hallam,Matthew L. Smith,Kwee Yong,Gordon Cook,James D. Cavenagh	2015	3
20	Velcade, Thalidomide, Dexamethasone and Panobinostat (VTD-P) for Patients with Relapsed and Relapsed/ Refractory Myeloma: Preliminary Results of the Muk-Six Phase I/IIa Trial Blood ·Rakesh Popat,Sarah Brown,Louise Flanagan,James D. Cavenagh	2014	6

About Louise Flanagan

Louise Flanagan is a scholar working on Hematology, Oncology and Molecular Biology, having authored 31 papers that have together received 302 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (21 papers), Protein Degradation and Inhibitors (17 papers), Histone Deacetylase Inhibitors Research (7 papers), Peptidase Inhibition and Analysis (6 papers), Chronic Lymphocytic Leukemia Research (2 papers), Cancer Mechanisms and Therapy (2 papers), Cancer Treatment and Pharmacology (2 papers) and Ubiquitin and proteasome pathways (2 papers). The work is most often cited by research in Hematology (122 citations), Oncology (109 citations) and Molecular Biology (170 citations). Louise Flanagan has collaborated with scholars based in United Kingdom, United States and Ireland. Frequent co-authors include Sarah Brown, Andrew Hall, Kwee Yong, Jamie Cavenagh, Martin Kaiser, Eric Low, Walter M. Gregory, Yong Du, Laura Moss and Jonathan Wadsley. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact